(0.21%) 5 472.14 points
(0.15%) 39 178 points
(0.67%) 17 851 points
(1.77%) $82.98
(-3.81%) $2.50
(-0.04%) $2 338.70
(0.03%) $29.57
(-2.42%) $989.60
(-0.14%) $0.932
(-0.10%) $10.67
(-0.04%) $0.790
(1.05%) $86.62
-0.93% $ 26.50
Live Chart Being Loaded With Signals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States...
Stats | |
---|---|
Volumen de hoy | 106 044 |
Volumen promedio | 573 711 |
Capitalización de mercado | 1.46B |
EPS | $0.00230 ( Q1 | 2024-05-08 ) |
Próxima fecha de ganancias | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-91.38 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.0320 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Bhatt Padmanabh P. | Buy | 14 491 | Common Stock |
2024-03-21 | Bhatt Padmanabh P. | Sell | 14 491 | Employee Stock Option (Right to Buy) |
2024-03-21 | Bhatt Padmanabh P. | Sell | 14 491 | Common Stock |
2024-03-20 | Bhatt Padmanabh P. | Sell | 400 | Employee Stock Option (Right to Buy) |
2024-03-20 | Bhatt Padmanabh P. | Buy | 400 | Common Stock |
INSIDER POWER |
---|
38.21 |
Last 100 transactions |
Buy: 802 366 | Sell: 356 762 |
Volumen Correlación
Supernus Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
ORGS | 0.887 |
VTYX | 0.868 |
CRTD | 0.863 |
XRTX | 0.863 |
SOUN | 0.859 |
BRKR | 0.857 |
LNW | 0.848 |
ARQQ | 0.846 |
ICLR | 0.846 |
BTF | 0.84 |
10 Correlaciones Más Negativas | |
---|---|
SABR | -0.835 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Supernus Pharmaceuticals Correlación - Moneda/Commodity
Supernus Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $607.52M |
Beneficio Bruto: | $438.88M (72.24 %) |
EPS: | $0.0241 |
FY | 2023 |
Ingresos: | $607.52M |
Beneficio Bruto: | $438.88M (72.24 %) |
EPS: | $0.0241 |
FY | 2022 |
Ingresos: | $667.24M |
Beneficio Bruto: | $580.02M (86.93 %) |
EPS: | $1.130 |
FY | 2021 |
Ingresos: | $579.78M |
Beneficio Bruto: | $504.71M (87.05 %) |
EPS: | $1.010 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico